Search
According to the latest Precedence Research report, the global biotechnology market size is expected to grow from $1.77 trillion in 2025 to $6.34 trillion by 2035, at a compound annual growth rate of 13.61%. AI-driven drug discovery, gene editing, and advanced biologics are becoming core growth engines.
The life sciences industry is accelerating its transformation toward precision medicine and AI-driven R&D. This article analyzes the latest developments of companies such as GSK, Takeda, Vertex, Novartis, Dassault Systèmes, and BMS, exploring how strategic acquisitions, regulatory approvals, and AI infrastructure are jointly shaping the new landscape of global healthcare technology.
In 2026, the biotechnology sector is moving from promise to execution. AI-driven R&D, breakthroughs in gene editing, regulatory reforms, and global transactions are reshaping the life sciences landscape. This article examines 26 key trends, covering dimensions such as scientific innovation, emerging markets, policy changes, and business models.
In 2026, the biotech and life sciences industry reaches a critical turning point. From AI-driven drug discovery to clinical breakthroughs in gene editing, from regulatory reforms to global capital flows, these 26 trends are reshaping the future of medical innovation.
This article is based on Salesforce's latest industry insights, analyzing the core applications, industry trends, market impact, and potential challenges of AI in healthcare, and exploring the industrial path of medical AI evolving from an assistive tool to healthcare system infrastructure.
In 2026, the biotech and life sciences field reaches a critical turning point. AI and machine learning become R&D infrastructure, gene editing, synthetic biology, and microbiome therapies move toward clinical application, and global regulatory frameworks are being rapidly restructured. This article outlines 26 major trends, analyzing how technology, markets, capital, and policy are reshaping the healthcare innovation ecosystem.
Researchers developed ALADYNOULLI, a Bayesian generative framework that jointly analyzes longitudinal electronic health records, age, and polygenic risk, identifying 21 reproducible disease features and improving disease prediction performance.
Analyze how regulatory pressure, demand explosion, and drug repurposing are reshaping R&D investment strategies and the market landscape for biopharmaceutical companies.
In the third quarter of 2026, the FDA will make approval decisions on multiple biotechnology products, involving areas such as IgA nephropathy, mRNA influenza vaccines, Duchenne muscular dystrophy cell therapy, and gene therapy. These decisions will profoundly impact the direction of the medical technology industry.
ZS Impact Institute report shows 90% of consumers trust AI health advice as much as that of doctors, early diagnosis could save $500 billion, promoting a zero-distance care model.
This week brought multiple major news in the biotechnology industry: Parabilis Medicines set a record with a $770.5 million IPO, Merck entered into a collaboration with Protillion worth up to $510 million for AI-driven drug discovery, a Lassa fever-rabies dual vaccine entered human trials, and CRISPR and mRNA delivery platforms demonstrated potential in treating cancer and Duchenne muscular dystrophy, respectively. These events reflect the accelerating convergence of capital, artificial intelligence, and gene editing technologies in medical innovation.
A recent Nature review points out that mRNA technology is moving from a vaccine tool toward a broader therapeutic platform. As bottlenecks around delivery, immune silencing, and tissue targeting are being addressed, the industry is entering the “mRNA therapeutics 2.0” phase.